Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review.
Luca UrsoAlberto NieriIlaria RambaldiAngelo CastelloLicia UccelliCorrado CittantiStefano PanareoIrene GagliardiMaria Rosaria AmbrosioMaria Chiara ZatelliMirco BartolomeiPublished in: Endocrine (2022)
In the last 10 years, several literature reports supported radioligand therapy (RLT) in neoadjuvant settings for pancreatic neuroendocrine tumors (PanNETs). Indeed, primary tumor shrinkage has been frequently reported following RLT in unresectable or borderline resectable PanNETs. Moreover, RLT-induced intratumoral modifications facilitate surgery, both on primary tumor and metastasis, having a great impact on progression free survival (PFS), overall survival (OS) and quality of life (QoL). However, prospective controlled investigations are necessary to confirm preliminary data and to define the best RLT scheme and the ideal patient that, in a multidisciplinary approach, should be referred to neoadjuvant RLT.
Keyphrases
- locally advanced
- neuroendocrine tumors
- rectal cancer
- free survival
- squamous cell carcinoma
- lymph node
- radiation therapy
- case report
- minimally invasive
- systematic review
- machine learning
- diabetic rats
- high glucose
- stem cells
- emergency department
- big data
- cell therapy
- adverse drug
- mesenchymal stem cells
- combination therapy
- replacement therapy
- coronary artery disease
- percutaneous coronary intervention
- visible light